7.Dan Feng, Qingzhen Liu, Qiaoling MA, et al. Elevated Dosing of Recombinant Human Thrombopoietin Accelerates Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Dosage-Optimization, Controlle...
汇报时间:Sunday, December 8, 2024: 1:00 PM 汇报地点:Room 11 (San Diego Convention Center) 19 摘要号:663 标题:Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess ...
在本届大会上,浙江大学医学院附属第一医院血液科金洁教授团队一项研究入选会议展示,并荣获2024 ASH 摘要成就奖(Abstract Achievement Awards)。该研究优化了骨髓石蜡标本处理流程,拓展了空间转录组在骨髓等含钙组织中的应用,并通过结合单细胞测序以及病理组织学解析了AML患者骨髓肿瘤微环境异质性和白血病干细胞(Leukemia s...
汇报时间:Sunday, December 8, 2024: 10:45 AM 汇报地点:Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego) 15 摘要号:484 标题:Rovadicitinib in Patients with Myelofibrosis Who Were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single Arm, Multicenter, Open-Label, Phase Ib Study 中...
$传奇生物(LEGN)$$金斯瑞生物科技(01548)$美国东部时间2024年11月5日上午9点,2024年ASH年度大会的abstract就会在网上公开(如果是Late Breaking Abstract的话,那么会在2024年11月25日公开)。在本年度的会议上,Arcellx和吉利德合作开发的BCMA靶点CAR-T药物Anito-cel也会发布iMMagine-1二期临床数据(NCT05396885,4L或以...
December 7-10, 2024 会场/Venue: San Diego Convention Center, San Diego, CA, USA ASH Annual Meeting & Exposition——The premier event in malignant and non-malignant hematology 摘要征文投稿: KEY DATES-关键日期 Abstract Submission Site Opens/摘要提交开始 ...
在本届大会上,北京高博医院潘静教授团队的研究成果备受瞩目,两项CAR-T疗法相关的研究(abstract 964及3466)入选大会,带来了诸多进展。为深入了解这些重磅研究成果,《肿瘤瞭望-血液时讯》现场特邀采访了潘教授,并围绕该两项研究和CAR-T治疗的话题进行了深入解读,现将该研究及采访内容整理如下。
《肿瘤瞭望-血液时讯》您团队的一项研究(abstract 452)入选了本届ASH会议的Oral,探讨了“通过成像质谱流式细胞术和空间转录组揭示EBV+弥漫性大B细胞淋巴瘤中调控抗淋巴瘤免疫和免疫化疗反应的免疫微环境”的课题,能否请您解读一下该研究和其临床价值? 林志娟教授:我们团队在本次大会上的口头报告阐释的是EBV+DLBCL...
December 7-10, 2024 会场/Venue: San Diego Convention Center, San Diego, CA, USA ASH Annual Meeting & Exposition——The premier event in malignant and non-malignant hematology 摘要征文投稿: KEY DATES-关键日期 Abstract Submission Site Opens/摘要提交开始 ...
If none of the abstract authors is an ASH member, the abstract must be sponsored by a current ASH member. ASH members are urged to use their best judgment in restricting sponsorship to a reasonable number of abstracts, keeping in mind that they are endorsing the authenticity and quality of ...